Par launches authorized generic version of AstraZeneca heart drug

Share this article:
Par Pharmaceuticals said it began shipping an authorized generic version of AstraZeneca beta blocker Toprol-XL. The announcement followed the launch of a 25-mg generic version of metoprolol in the US by Eon Labs, part of Sandoz. Par’s authorized generic also is being distributed in a 25-mg dosage, a size which accounts for about 20% of Toprol-XL US sales, AZ said. Toprol-XL had $838.9 million in sales during the first six months of 2006 and $1.49 billion in sales in 2005, according to IMS Health. An extended-release pill whose patent expires in September 2007, Toprol-XL’s patent was deemed invalid earlier this year in litigation involving KV Pharmaceutical, Andrx Pharmaceuticals, Andrx Corp. and Eon Labs Manufacturing. AZ appealed that decision and, notwithstanding its deal with Par, said it will continue to sell branded Toprol-XL in the US.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...